We are now more than midway through Cervical Health Awareness Month. So far, we have reviewed cervical health issues such as the HPV vaccine and how it can help protect against more strains of HPV than any other vaccine on the market. We have also taken a look at what the WHO advises regarding vaccination, screening and cancer prevention. Now, we turn to PATH, a group that is trying to help individuals and governments provide care for and prevent the spread of cervical cancers.
Since its beginnings in 1977, when PATH had only three staff members and a dream, the group has partnered with global health leaders in order to find affordable and effective solutions for HPV screening and vaccinations. Through these screenings the group hopes to decrease the number of deaths due to cervical and other related cancers and help improve women’s health throughout the world.
One of PATH’s major focuses has been getting screenings to areas that could not otherwise offer this medical service (not entirely unlike Matternet and Project C.U.R.E). Through a partnership with QIAGEN, a German molecular diagnostics company, careHPVTM was developed, and this test provides a faster, more cost effective, and less technically advanced way of testing for cancer-causing HPV variants than the conventional Pap test. PATH is also working with another company on developing a similar easy-to-use test that will check for cancerous cells and not just the HPV infection.